- Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Thursday, Passage Bio Inc (PASG:NSQ) closed at 1.22, -31.84% below its 52-week high of 1.79, set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.25 |
---|---|
High | 1.25 |
Low | 1.18 |
Bid | 1.16 |
Offer | 1.35 |
Previous close | 1.26 |
Average volume | 67.66k |
---|---|
Shares outstanding | 61.64m |
Free float | 61.34m |
P/E (TTM) | -- |
Market cap | 77.67m USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼